Brain injury, at Department of Neurology Ⅱ, The Affiliated Hospital of Shandong Second Medical University, China.
🌟 Dr. Yanqiang Wang is a distinguished neurologist specializing in the pathogenesis and neuroprotection of ischemic brain injury and Parkinson’s disease. He serves as a director at the Affiliated Hospital of Weifang Medical University, leading research on cerebrovascular diseases, particularly ischemic stroke and neuromyelitis optica spectrum disorders. With extensive clinical experience, he has held key positions in multiple prestigious institutions, including the University of Washington. His academic journey spans a Ph.D. from Sun Yat-sen University and postdoctoral research at Xuzhou Medical University. Dr. Wang has made significant contributions to neurology, authoring numerous peer-reviewed publications in high-impact journals. His research advances innovative treatments and diagnostic approaches, influencing both academia and clinical practice.
Professional Profile
Scopus
Education
🎓 Dr. Yanqiang Wang has an extensive academic background in neurology. He earned his Master’s degree from Xuzhou Medical University (2003-2006), where he conducted research on the pathogenesis of Parkinson’s disease. He then pursued a Ph.D. at Sun Yat-sen University (2012-2015), focusing on the pathogenesis and clinical study of ischemic stroke and neuromyelitis optica spectrum disorders. Furthering his expertise, he completed a postdoctoral fellowship at Xuzhou Medical University (2016-2019), where his work centered on ischemic stroke mechanisms and novel treatment approaches. His academic journey has provided him with a robust foundation in neurological research, making him a key contributor to the field of cerebrovascular diseases.
Experience
👩🌾 Dr. Wang has a rich clinical and research career spanning over two decades. He began as a Resident and Attending Doctor in the Department of Immunology and Rheumatology at the Affiliated Hospital of Weifang Medical University (2006-2012), where he focused on systemic lupus erythematosus and rheumatoid arthritis. Since 2015, he has served as an Attending Doctor, Vice Director, and Director at the Affiliated Hospital of Shandong Second Medical University, specializing in cerebrovascular diseases. In 2020, he held a Vice Director position at the University of Washington, further expanding his expertise in stroke research. His diverse experience has positioned him as a leading expert in neurology and cerebrovascular disorders.
Research Interests
🌍 Dr. Wang’s research primarily revolves around cerebrovascular diseases, neuroprotection, and ischemic stroke. His focus includes the pathogenesis of ischemic stroke, neuromyelitis optica spectrum disorders, and Parkinson’s disease. His studies explore mechanisms underlying brain injury, neuroinflammation, and potential neuroprotective strategies. Additionally, he investigates stroke rehabilitation, angiogenesis, and novel therapeutic interventions, including the role of vitamin D and the gut-brain axis in neuroprotection. Dr. Wang’s work contributes to the development of innovative treatments and diagnostic tools for neurological disorders, bridging the gap between clinical applications and cutting-edge research.
Awards
🏆 Dr. Wang has received numerous accolades recognizing his contributions to neurology and cerebrovascular research. His awards include prestigious honors from national and international medical organizations. He has been recognized for his groundbreaking research in ischemic stroke and neuroprotection, earning distinctions such as “Outstanding Neurology Researcher” and “Best Clinical Investigator” from leading institutions. His contributions to medical education and innovative clinical approaches have also been acknowledged with teaching excellence awards. His commitment to advancing neurology continues to earn him significant recognition within the scientific community.
Top Noted Publications
📚 Dr. Wang has authored numerous peer-reviewed publications in esteemed journals. Below are selected works with hyperlinks:
1. Li Y, et al. (2022). “1,25-D3 attenuates cerebral ischemia injury via the AMPK/AKT/GSK3β pathway.” Frontiers in Aging Neuroscience. Cited by: 15.
This study investigated the neuroprotective effects of 1,25-dihydroxyvitamin D3 (1,25-D3) on cerebral ischemia injury. The authors found that 1,25-D3 administration reduced infarct size and improved neurological function scores in animal models. Mechanistically, 1,25-D3 activated the vitamin D receptor (VDR) and upregulated the expression of transforming growth factor-beta (TGF-β), phosphorylated AMP-activated protein kinase (p-AMPK), phosphorylated AKT (p-AKT), phosphorylated glycogen synthase kinase-3 beta (p-GSK-3β), vascular endothelial growth factor (VEGF), ATP, and succinate dehydrogenase. Concurrently, it downregulated the expression of P53, cytochrome c (CytC), caspase-3, reactive oxygen species (ROS), and malondialdehyde (MDA). The study suggests that 1,25-D3 exerts neuroprotective effects in cerebral ischemia by modulating mitochondrial metabolism through the AMPK/AKT/GSK3β pathway.
2. Zhang Y, et al. (2022). “1α,25-Dihydroxyvitamin D3 promotes angiogenesis after cerebral ischemia injury.” Frontiers in Cardiovascular Medicine. Cited by: 10.
This research focused on the role of 1α,25-dihydroxyvitamin D3 (1,25-D3) in promoting angiogenesis following cerebral ischemia injury in rats. The findings indicated that 1,25-D3 treatment reduced cerebral infarction volume, enhanced cerebral blood flow recovery, and increased the expression of VDR, TGF-β, phosphorylated Smad2 (p-Smad2), phosphorylated Smad3 (p-Smad3), and VEGF. Additionally, 1,25-D3 significantly increased the number of IB4-positive tip cells and the length of CD31-positive vasculature in the peri-infarct area compared to controls. These effects were partially reversed by the VDR antagonist pyridoxal-5-phosphate (P5P), suggesting that 1,25-D3 promotes angiogenesis after cerebral ischemia by upregulating the TGF-β/Smad2/3 signaling pathway via VDR activation.
3. Zhao Y, et al. (2023). “Atherosclerotic basilar artery occlusion revascularized by drug-coated balloon dilation.” International Journal of Neuroscience. Cited by: 8.
This study explored the efficacy of drug-coated balloon (DCB) dilation in revascularizing atherosclerotic basilar artery occlusion. The authors reported that DCB dilation effectively restored blood flow in patients with basilar artery occlusion due to atherosclerosis. The procedure was associated with favorable clinical outcomes and a low rate of restenosis during follow-up. The study suggests that DCB dilation is a promising therapeutic option for revascularization in atherosclerotic basilar artery occlusion.
4. Sun S, et al. (2020). “Cerebellar hemorrhage as the primary manifestation of hyperacute disseminated encephalomyelitis.” Acta Neurologica Belgica. Cited by: 12.
This case report described a rare presentation of hyperacute disseminated encephalomyelitis (ADEM) manifesting primarily as cerebellar hemorrhage. The patient presented with sudden-onset cerebellar symptoms, and imaging revealed cerebellar hemorrhage. Further investigations led to the diagnosis of ADEM. The report highlights the importance of considering ADEM in the differential diagnosis of cerebellar hemorrhage, especially in the absence of typical risk factors for hemorrhage.
5. Wu N, et al. (2023). “Clinical features of ischemic stroke in nonvalvular atrial fibrillation with intracranial atherosclerosis.” Brain and Behavior. Cited by: 7.
This study examined the clinical characteristics of ischemic stroke patients with nonvalvular atrial fibrillation (NVAF) and concomitant intracranial atherosclerosis (ICAS). The authors found that patients with both NVAF and ICAS had a higher prevalence of previous stroke or transient ischemic attack, more severe neurological deficits at admission, and worse functional outcomes at discharge compared to patients with NVAF alone. The study suggests that the presence of ICAS in patients with NVAF may be associated with more severe stroke and poorer outcomes.
Conclusion
Dr. Yanqiang Wang is a highly accomplished researcher in neurology, with a strong record in cerebrovascular diseases, neuroprotection, and ischemic brain injury. His extensive publication record, international collaborations, and clinical expertise make him a strong contender for the Best Researcher Award. However, strengthening his profile in terms of grant acquisition, mentorship, and interdisciplinary research would further solidify his standing.